Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Website: cariboubio.com



Growth: Good revenue growth rate 50.0%, there is acceleration compared to average historical growth rates -75.0%

Profitability: LTM EBITDA margin is negative, -1 440.0%. On average the margin is decreasing steadily. Gross margin is low, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -150.7% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 5.3% higher than minimum and 87.6% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -70.7x by EV / Sales multiple

Key Financials (Download financials)

Ticker: CRBU
Share price, USD:  (+3.6%)3.77
year average price 5.39  


year start price 4.44 2023-05-05

min close price 3.58 2023-11-01

max close price 8.26 2024-02-27

current price 3.77 2024-05-04
Common stocks: 60 705 399

Dividend Yield:  0.0%
Last revenue growth (y/y):  50.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  -75.0%
Historical growth of EBITDA:  0.0%
EV / Sales: 21.8x
Margin (EBITDA LTM / Revenue): -1 440.0%
Fundamental value created in LTM:
Market Cap ($m): 229
Net Debt ($m): -120
EV (Enterprise Value): 109
Price to Book: 0.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-24GlobeNewsWire

Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

2024-04-18Seeking Alpha

Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

2024-03-14Zacks Investment Research

All You Need to Know About Caribou Biosciences, Inc. (CRBU) Rating Upgrade to Buy

2024-03-12The Motley Fool

Why Caribou Biosciences Stock Is Crashing Today

2024-02-15GlobeNewsWire

Caribou Biosciences to Participate in Upcoming Investor Conferences

2023-12-13InvestorPlace

3 Gene-Editing Stocks With the Potential to Mint Millionaires

2023-12-08Zacks Investment Research

Caribou Biosciences, Inc. (CRBU) Upgraded to Buy: What Does It Mean for the Stock?

2023-12-07InvestorPlace

Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy

2023-11-26Seeking Alpha

Caribou Biosciences: Upcoming CB-010 Data Could Send The Bears Packing

2023-09-23The Motley Fool

1 Gene Editing Stock to Buy Now, and 1 to Sell
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CRBU CRBU CRBU CRBU CRBU CRBU
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-11 2023-11-07 2023-08-08 2023-05-09 2023-03-09 2022-11-08
acceptedDate 2024-03-11 16:25:52 2023-11-07 16:03:49 2023-08-08 16:06:44 2023-05-09 16:07:42 2023-03-09 17:18:16 2022-11-08 16:23:13
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 4M 24M 4M 4M 4M 3M
costOfRevenue 2M 2M 1M 0 0 0
grossProfit 2M 22M 3M 4M 4M 3M
grossProfitRatio 0.445 0.911 0.700 1.000 1.000 1.000
researchAndDevelopmentExpenses 31M 29M 27M 26M 26M 20M
generalAndAdministrativeExpenses 10M 10M 10M 9M 9M 10M
sellingAndMarketingExpenses -2M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 8M 10M 10M 9M 9M 10M
otherExpenses 3M 5M 3M 3M 4M 0
operatingExpenses 39M 38M 37M 35M 34M 30M
costAndExpenses 41M 38M 37M 35M 34M 30M
interestIncome 0 5M 3M 0 0 0
interestExpense 0 0 0 -3M -4M -31 000
depreciationAndAmortization 2M 2M 617 000 604 000 60 000 419 000
ebitda -35M -15M -33M -31M -31M -26M
ebitdaratio -9.969 -0.618 -8.759 -8.713 -8.266 -7.907
operatingIncome -37M -15M -33M -31M -31M -27M
operatingIncomeRatio -10.523 -0.618 -8.753 -8.885 -8.282 -8.034
totalOtherIncomeExpensesNet 3M 5M 3M 3M 4M -110 000
incomeBeforeTax -34M -10M -30M -28M -27M -27M
incomeBeforeTaxRatio -9.644 -0.423 -7.861 -8.008 -7.291 -8.068
incomeTaxExpense 193 000 -2M -639 000 -3M 70 000 110 000
netIncome -35M -10M -30M -25M -27M -27M
netIncomeRatio -9.698 -0.423 -7.861 -7.135 -7.310 -8.101
eps -0.390 -0.120 -0.480 -0.410 -0.440 -0.440
epsdiluted -0.390 -0.120 -0.480 -0.410 -0.440 -0.440
weightedAverageShsOut 88M 84M 61M 61M 61M 61M
weightedAverageShsOutDil 88M 84M 61M 61M 61M 61M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CRBU CRBU CRBU CRBU CRBU CRBU
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-11 2023-11-07 2023-08-08 2023-05-09 2023-03-09 2022-11-08
acceptedDate 2024-03-11 16:25:52 2023-11-07 16:03:49 2023-08-08 16:06:44 2023-05-09 16:07:42 2023-03-09 17:18:16 2022-11-08 16:23:13
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 51M 104M 66M 53M 58M 82M
shortTermInvestments 278M 234M 193M 176M 189M 211M
cashAndShortTermInvestments 329M 338M 293M 229M 317M 293M
netReceivables 4M 5M 4M 5M 5M 5M
inventory 0 5M -29M 5M -63M 0
otherCurrentAssets 6M 2M 1M 1M 1M 1M
totalCurrentAssets 339M 351M 269M 239M 260M 307M
propertyPlantEquipmentNet 40M 39M 39M 36M 35M 34M
goodwill 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0
longTermInvestments 51M 66M 41M 70M 77M 57M
taxAssets 9M 0 0 0 0 0
otherNonCurrentAssets 2M 2M 1M 1M 2M 1M
totalNonCurrentAssets 102M 107M 81M 108M 114M 92M
otherAssets 0 0 0 0 0 0
totalAssets 441M 458M 350M 347M 374M 399M
accountPayables 3M 2M 4M 3M 1M 1M
shortTermDebt 2M 1M 1M 1M 966 000 912 000
taxPayables 0 0 0 0 0 0
deferredRevenue 3M 3M 13M 11M 10M 12M
otherCurrentLiabilities 21M 18M 16M 13M 16M 15M
totalCurrentLiabilities 28M 25M 34M 27M 28M 29M
longTermDebt 26M 26M 26M 26M 27M 27M
deferredRevenueNonCurrent 6M 7M 18M 14M 16M 15M
deferredTaxLiabilitiesNonCurrent 9M 381 000 380 000 382 000 381 000 475 000
otherNonCurrentLiabilities 3M 1M 1M 1M 2M 32M
totalNonCurrentLiabilities 44M 35M 46M 42M 45M 46M
otherLiabilities 1.000 0 0 0 0 0
capitalLeaseObligations 26M 27M 27M 27M 28M 28M
totalLiabilities 73M 59M 80M 69M 73M 75M
preferredStock 0 0 0 0 0 0
commonStock 8000.000 8000.000 6000.000 6000.000 6000.000 6000.000
retainedEarnings -299M -265M -255M -225M -197M -170M
accumulatedOtherComprehensiveIncomeLoss 30 000 -981 000 -1M -730 000 -2M -2M
othertotalStockholdersEquity 668M 664M 525M 504M 500M 496M
totalStockholdersEquity 368M 398M 269M 278M 301M 324M
totalEquity 368M 398M 269M 278M 301M 324M
totalLiabilitiesAndStockholdersEquity 441M 458M 350M 347M 374M 399M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 441M 458M 350M 347M 374M 399M
totalInvestments 329M 242M 201M 183M 197M 219M
totalDebt 27M 27M 27M 27M 28M 28M
netDebt -24M -77M -39M -25M -31M -54M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CRBU CRBU CRBU CRBU CRBU CRBU
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-11 2023-11-07 2023-08-08 2023-05-09 2023-03-09 2022-11-08
acceptedDate 2024-03-11 16:25:52 2023-11-07 16:03:49 2023-08-08 16:06:44 2023-05-09 16:07:42 2023-03-09 17:18:16 2022-11-08 16:23:13
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -35M -10M -30M -28M -27M -27M
depreciationAndAmortization 2M 2M 617 000 589 000 506 000 450 000
deferredIncomeTax -5M -2M -2M 0 -95 000 0
stockBasedCompensation 4M 3M 4M 3M 3M 3M
changeInWorkingCapital 5M -22M 12M -2M -128 000 -707 000
accountsReceivables 1M -367 000 767 000 -1M 195 000 127 000
inventory 0 819 000 4M 0 0 0
accountsPayables 730 000 -953 000 540 000 2M -153 000 989 000
otherWorkingCapital 3M -22M 6M -3M -170 000 -2M
otherNonCashItems 8M 666 000 169 000 -1M -1M 2M
netCashProvidedByOperatingActivities -21M -29M -15M -28M -25M -22M
investmentsInPropertyPlantAndEquipment -2M -5M -3M -2M -2M -2M
acquisitionsNet 29M 64M -14M 0 300 000 0
purchasesOfInvestments -84M -176M -59M -76M -87M -71M
salesMaturitiesOfInvestments 55M 112M 72M 99M 90M 64M
otherInvestingActivites -29M -64M 14M 0 -300 000 0
netCashUsedForInvestingActivites -31M -68M 11M 21M 1M -8M
debtRepayment 0 0 0 0 0 0
commonStockIssued -43 000 134M 17M 1M 2M 0
commonStockRepurchased -43 000 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 0 753 000 236 000 519 000 -2M 654 000
netCashUsedProvidedByFinancingActivities -43 000 135M 18M 2M 127 000 654 000
effectOfForexChangesOnCash 0 0 0 0 0 0
netChangeInCash -53M 38M 13M -6M -24M -30M
cashAtEndOfPeriod 51M 104M 66M 53M 58M 82M
cashAtBeginningOfPeriod 104M 66M 53M 58M 82M 112M
operatingCashFlow -21M -29M -15M -28M -25M -22M
capitalExpenditure -2M -5M -3M -2M -2M -2M
freeCashFlow -24M -34M -18M -30M -27M -24M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-03-11 20:05 ET
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2024-03-05 21:30 ET
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
2024-02-15 21:05 ET
Caribou Biosciences to Participate in Upcoming Investor Conferences
2024-01-07 16:00 ET
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
2023-12-12 21:02 ET
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
2023-11-07 21:00 ET
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
2023-11-06 13:00 ET
Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board
2023-11-01 20:05 ET
Caribou Biosciences to Participate in Upcoming Investor Conferences
2023-10-18 12:00 ET
Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
2023-09-27 12:00 ET
Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer
2023-08-29 20:00 ET
Caribou Biosciences to Participate in Upcoming Investor Conferences
2023-08-08 20:00 ET
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
2023-07-14 03:15 ET
Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering
2023-07-13 20:03 ET
Caribou Biosciences Announces Proposed Public Offering of Common Stock
2023-07-13 20:01 ET
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
2023-07-06 12:00 ET
Caribou Biosciences Announces $25 Million Equity Investment from Pfizer
2023-05-31 20:00 ET
Caribou Biosciences to Participate in Upcoming Investor Conferences
2023-05-09 20:00 ET
Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
2023-05-08 13:00 ET
Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board
2023-05-01 20:00 ET
Caribou Biosciences to Participate in Upcoming Investor Conferences
2023-04-17 17:30 ET
Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting
2023-04-04 12:00 ET
Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
2023-03-29 12:00 ET
Caribou Biosciences Initiates Dose Expansion Portion of CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients
2023-03-29 12:00 ET
Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
2023-03-09 22:09 ET
Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
2023-03-08 21:05 ET
Caribou Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
2023-02-01 21:05 ET
Caribou Biosciences to Participate in Upcoming Investor Conferences
2023-01-03 21:05 ET
Caribou Biosciences to Present at 41st Annual J.P. Morgan Healthcare Conference
2022-12-12 13:01 ET
Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress
2022-12-12 13:00 ET
Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy
2022-11-29 14:00 ET
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy
2022-11-21 14:00 ET
Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
2022-11-08 21:00 ET
Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
2022-11-07 21:05 ET
Caribou Biosciences to Participate in Upcoming Investor Conferences
2022-11-03 13:00 ET
Caribou Biosciences to Present ANTLER Trial-in-Progress Poster at the 64th American Society of Hematology Annual Meeting
2022-10-18 13:00 ET
Caribou Biosciences Presents Case Report on Long-term Follow up of First Patient Dosed in Phase 1 ANTLER Trial at the Lymphoma, Leukemia, & Myeloma Congress 2022
2022-08-31 20:05 ET
Caribou Biosciences to Participate in Upcoming Investor Conferences
2022-08-09 20:00 ET
Caribou Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
2022-06-10 07:00 ET
Caribou Biosciences Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress
2022-06-01 20:05 ET
Caribou Biosciences Announces Webcast Conference Call to Highlight Initial CB-010 ANTLER Phase 1 Data Presentation at EHA on June 10, 2022
2022-05-16 20:05 ET
Caribou Biosciences Presents Data on Mechanism Underlying Superior Specificity of Caribou’s chRDNA Genome-Editing Technology in Primary Human T cells
2022-05-12 14:00 ET
Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy
2022-05-11 20:00 ET
Caribou Biosciences Announces Appointment of David Johnson to its Board of Directors
2022-05-09 20:05 ET
Caribou Biosciences Reports First Quarter 2022 Financial Results and Provides Business Updates
2022-05-03 20:05 ET
Caribou Biosciences to Present at Upcoming Investor Conference
2022-05-02 20:30 ET
Caribou Biosciences Announces Presentation of chRDNA Platform Data at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT)
2022-04-25 20:05 ET
Caribou Biosciences to Share CB-010 Initial Clinical Data at the Upcoming European Hematology Association (EHA) 2022 Hybrid Congress
2022-04-08 17:07 ET
Caribou Biosciences Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 at the American Association for Cancer Research (AACR) Annual Meeting
2022-03-21 20:02 ET
Caribou Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
2022-03-09 01:19 ET
Caribou Biosciences to Present Preclinical Data on CB-011, an Immune-Cloaked Allogeneic Anti-BCMA CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
2022-03-07 21:10 ET
Caribou Biosciences to Present at Upcoming Investor Conferences
2022-02-07 21:05 ET
Caribou Biosciences to Present at the SVB Leerink 11th Annual Global Healthcare Conference
2022-01-18 13:00 ET
Caribou Biosciences Appoints Syed Rizvi, M.D., as Chief Medical Officer
2022-01-04 21:05 ET
Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference
2021-11-17 21:05 ET
Caribou Biosciences to Present at Upcoming Investor Conferences
2021-11-09 21:05 ET
Caribou Biosciences Provides Business Update and Reports Third Quarter 2021 Financial Results
2021-11-08 14:00 ET
Caribou Biosciences Appoints Dara Richardson-Heron, M.D., to its Board of Directors and Ruhi Khan as Chief Business Officer
2021-10-20 20:00 ET
Caribou Biosciences to Present at Upcoming Investor Conferences
2021-09-29 20:05 ET
Caribou Biosciences Appoints Biotechnology Industry Veteran Ran Zheng to its Board of Directors
2021-09-27 20:05 ET
Caribou Biosciences to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
2021-09-02 20:05 ET
Caribou Biosciences Announces Publication of Data Demonstrating High Specificity Genome Editing with its Proprietary chRDNA Technology
2021-09-02 20:05 ET
Caribou Biosciences Provides Business Update and Reports Second Quarter 2021 Financial Results
2021-09-01 12:00 ET
Caribou Biosciences to Participate in Citi’s 16Th Annual BioPharma Virtual Conference
2021-08-25 20:00 ET
Caribou Biosciences Appoints Nancy Whiting, Pharm.D., to its Board of Directors
2021-07-27 20:05 ET
Caribou Biosciences Announces Closing of Upsized Initial Public Offering
2021-07-23 01:09 ET
Caribou Biosciences Announces Pricing of Upsized Initial Public Offering

SEC forms

Show financial reports only

SEC form 10
2024-03-11 16:25 ET
Caribou Biosciences, Inc. published news for 2023 q4
SEC form 10
2024-03-11 00:00 ET
Caribou Biosciences, Inc. published news for 2023 q4
SEC form 8
2024-03-11 00:00 ET
Caribou Biosciences, Inc. published news for 2023 q4
SEC form 8
2024-03-11 00:00 ET
Caribou Biosciences, Inc. reported for 2023 q4
SEC form 10
2023-11-07 16:03 ET
Caribou Biosciences, Inc. reported for 2023 q3
SEC form 8
2023-11-07 16:02 ET
Caribou Biosciences, Inc. reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Caribou Biosciences, Inc. reported for 2023 q3
SEC form 10
2023-08-08 16:06 ET
Caribou Biosciences, Inc. reported for 2023 q2
SEC form 6
2023-08-08 16:03 ET
Caribou Biosciences, Inc. reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Caribou Biosciences, Inc. reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Caribou Biosciences, Inc. reported for 2023 q2
SEC form 6
2023-07-14 18:33 ET
Caribou Biosciences, Inc. published news for 2023 q2
SEC form 6
2023-07-14 16:22 ET
Caribou Biosciences, Inc. published news for 2023 q2
SEC form 6
2023-07-13 16:23 ET
Caribou Biosciences, Inc. published news for 2023 q2
SEC form 6
2023-07-13 16:17 ET
Caribou Biosciences, Inc. published news for 2023 q2
SEC form 8
2023-07-13 00:00 ET
Caribou Biosciences, Inc. published news for 2023 q2
SEC form 6
2023-07-06 08:01 ET
Caribou Biosciences, Inc. published news for 2023 q2
SEC form 6
2023-06-16 16:05 ET
Caribou Biosciences, Inc. published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Caribou Biosciences, Inc. reported for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Caribou Biosciences, Inc. reported for 2023 q1
SEC form 6
2023-04-04 08:00 ET
Caribou Biosciences, Inc. published news for 2023 q1
SEC form 6
2023-03-29 08:00 ET
Caribou Biosciences, Inc. published news for 2022 q4
SEC form 6
2023-03-29 08:00 ET
Caribou Biosciences, Inc. published news for 2022 q4
SEC form 6
2023-03-24 16:05 ET
Caribou Biosciences, Inc. published news for 2022 q4
SEC form 10
2023-03-09 17:18 ET
Caribou Biosciences, Inc. reported for 2022 q4
SEC form 6
2023-03-09 17:13 ET
Caribou Biosciences, Inc. reported for 2022 q4
SEC form 8
2023-03-09 00:00 ET
Caribou Biosciences, Inc. reported for 2022 q4
SEC form 10
2023-03-09 00:00 ET
Caribou Biosciences, Inc. reported for 2022 q4
SEC form 6
2022-12-16 16:05 ET
Caribou Biosciences, Inc. published news for 2022 q3
SEC form 6
2022-12-12 08:00 ET
Caribou Biosciences, Inc. published news for 2022 q3
SEC form 6
2022-11-29 09:00 ET
Caribou Biosciences, Inc. published news for 2022 q3
SEC form 6
2022-11-21 09:00 ET
Caribou Biosciences, Inc. published news for 2022 q3
SEC form 10
2022-11-08 16:23 ET
Caribou Biosciences, Inc. reported for 2022 q3
SEC form 6
2022-11-08 16:05 ET
Caribou Biosciences, Inc. reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Caribou Biosciences, Inc. reported for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Caribou Biosciences, Inc. reported for 2022 q3
SEC form 6
2022-11-03 09:00 ET
Caribou Biosciences, Inc. published news for 2022 q3
SEC form 6
2022-10-18 09:00 ET
Caribou Biosciences, Inc. published news for 2022 q3
SEC form 6
2022-09-22 18:42 ET
Caribou Biosciences, Inc. published news for 2022 q2
SEC form 6
2022-09-22 16:05 ET
Caribou Biosciences, Inc. published news for 2022 q2
SEC form 6
2022-08-12 16:02 ET
Caribou Biosciences, Inc. published news for 2022 q2
SEC form 6
2022-08-11 16:04 ET
Caribou Biosciences, Inc. published news for 2022 q2
SEC form 10
2022-08-09 16:11 ET
Caribou Biosciences, Inc. reported for 2022 q2
SEC form 6
2022-08-09 16:04 ET
Caribou Biosciences, Inc. published news for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Caribou Biosciences, Inc. published news for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Caribou Biosciences, Inc. reported for 2022 q2
SEC form 6
2022-07-18 16:04 ET
Caribou Biosciences, Inc. published news for 2022 q2
SEC form 6
2022-07-15 16:06 ET
Caribou Biosciences, Inc. published news for 2022 q2
SEC form 6
2022-06-10 07:54 ET
Caribou Biosciences, Inc. published news for 2022 q1
SEC form 6
2022-06-01 16:14 ET
Caribou Biosciences, Inc. published news for 2022 q1
SEC form 6
2022-05-12 10:03 ET
Caribou Biosciences, Inc. published news for 2022 q1
SEC form 6
2022-05-11 16:07 ET
Caribou Biosciences, Inc. published news for 2022 q1
SEC form 10
2022-05-09 16:23 ET
Caribou Biosciences, Inc. published news for 2022 q1
SEC form 6
2022-05-09 16:11 ET
Caribou Biosciences, Inc. published news for 2022 q1
SEC form 8
2022-05-09 00:00 ET
Caribou Biosciences, Inc. reported for 2022 q1
SEC form 10
2022-05-09 00:00 ET
Caribou Biosciences, Inc. reported for 2022 q1
SEC form 6
2022-04-25 16:18 ET
Caribou Biosciences, Inc. published news for 2022 q1
SEC form 10
2022-03-21 16:19 ET
Caribou Biosciences, Inc. published news for 2021 q4
SEC form 6
2022-03-21 16:13 ET
Caribou Biosciences, Inc. published news for 2021 q4
SEC form 8
2022-03-21 00:00 ET
Caribou Biosciences, Inc. published news for 2021 q4
SEC form 10
2022-03-21 00:00 ET
Caribou Biosciences, Inc. published news for 2021 q4
SEC form 6
2022-01-19 16:19 ET
Caribou Biosciences, Inc. published news for 2021 q4
SEC form 6
2022-01-18 08:02 ET
Caribou Biosciences, Inc. published news for 2021 q4
SEC form 10
2021-11-09 16:22 ET
Caribou Biosciences, Inc. published news for 2021 q3
SEC form 6
2021-11-09 16:12 ET
Caribou Biosciences, Inc. published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Caribou Biosciences, Inc. published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Caribou Biosciences, Inc. published news for 2021 q3
SEC form 6
2021-11-08 09:10 ET
Caribou Biosciences, Inc. published news for 2021 q3
SEC form 6
2021-10-01 17:37 ET
Caribou Biosciences, Inc. published news for 2021 q3
SEC form 6
2021-09-29 16:15 ET
Caribou Biosciences, Inc. published news for 2021 q2
SEC form 10
2021-09-02 16:28 ET
Caribou Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-02 16:18 ET
Caribou Biosciences, Inc. published news for 2021 q2
SEC form 8
2021-09-02 00:00 ET
Caribou Biosciences, Inc. published news for 2021 q2
SEC form 10
2021-09-02 00:00 ET
Caribou Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-08-25 16:11 ET
Caribou Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-07-28 16:05 ET
Caribou Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-07-23 06:10 ET
Caribou Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-07-22 21:01 ET
Caribou Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-07-22 21:00 ET
Caribou Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-07-22 21:00 ET
Caribou Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-07-22 20:58 ET
Caribou Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-07-22 20:58 ET
Caribou Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-07-22 20:57 ET
Caribou Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-07-22 20:56 ET
Caribou Biosciences, Inc. published news for 2021 q2